News

Leading Healthcare Regulatory Group Joins Arnold & Porter

July 9, 2008

Four-Person Team Bolsters Already Strong False Claims, Fraud & Abuse, Reimbursement and FDA Practices

WASHINGTON, D.C., July 9, 2008 -- Arnold & Porter LLP announced today that a four-person healthcare team has joined the firm. The group brings substantial experience in a number of growing areas for the firm, including false claims, fraud and abuse, healthcare coverage, and reimbursement and coding.

Alan Reider, Allison Shuren, Paul Rudolf and Thomas Gustafson have joined the firm in Washington, DC.

"Our historic strength in the FDA and healthcare regulatory field has been vital for many of our key clients," said Chair Thomas Milch. "This team has the expertise and the in-depth background that we need to strengthen this practice even further. We believe they are an excellent addition to the firm."

"This group will provide a solid bench of additional expertise in an area of increasing importance for our clients and one in which we are growing," said Daniel Kracov, head of Arnold & Porter's FDA and Healthcare Practice.

  • Mr. Reider held senior management positions at his former firm, including a prior position as chair of the healthcare practice for more than 20 years. He represents national healthcare corporations, manufacturers, institutional providers and individuals on a range of enforcement, investigational and regulatory matters. He has defended clients in some of the largest healthcare fraud and abuse enforcement matters brought by the Federal government.
  • Ms. Shuren, who has practiced as a critical care nurse practitioner, focuses on healthcare matters involving Medicare coverage, fraud and abuse, and corporate compliance programs. Her clients include pharmaceutical, biotechnology and medical device companies, hospital and academic medical centers, physician groups, trade associations and other healthcare entities.
  • Dr. Rudolf, MD, joins as a senior healthcare advisor. He has experience in Medicare and FDA matters, including Medicare coverage, coding and reimbursement issues for manufacturers, hospitals, physician groups and other healthcare companies. He is a veteran of both CMS, where he was an expert on coding and reimbursement for Medicare, and FDA, where he advised on key policy issues in the Office of the Commissioner. He also has more than15 years of experience practicing medicine. Dr. Rudolf is not admitted to the practice of law in the District of Columbia.
  • Dr. Gustafson, PhD, joins as a senior policy advisor. He concentrates on Medicare payment issues and on health policy issues. He had a long and distinguished record of service at the US Department of Health and Human Services, where he served as acting director of the Center for Medicare Management (CMM), among other positions, and oversaw a sweeping reform of Medicare's payment system for outpatient hospital services.

Arnold & Porter has a leading FDA and healthcare practice that serves clients in the pharmaceutical, biotechnology, medical device and diagnostic industries, responding to complex regulatory and compliance challenges in the US and Europe. The practice has substantial experience in the regulatory issues faced by food, dietary supplement and cosmetic product companies. More than fifty lawyers
in the US and Europe are practicing in this area, many of whom have previous government agency experience or have served as medical doctors, scientists, and public policy specialists.

Earlier this year, Edith Marshall joined Arnold & Porter's Washington, DC office as counsel to advise clients on Medicare, Medicaid and other public health issues including drug pricing, reimbursement, fraud and abuse, and privacy.

Arnold & Porter LLP, an international law firm of over 650 attorneys, has offices in Washington, DC, Northern Virginia, New York, Los Angeles, Denver, San Francisco, London and Brussels. The firm, founded in 1946, maintains more than 25 practice areas spanning a broad spectrum of the law, with a primary focus on litigation, transactional matters and regulatory issues.

Email Disclaimer